CN103717609B - 聚(adp-核糖)聚合酶的三环抑制剂 - Google Patents

聚(adp-核糖)聚合酶的三环抑制剂 Download PDF

Info

Publication number
CN103717609B
CN103717609B CN201280024255.0A CN201280024255A CN103717609B CN 103717609 B CN103717609 B CN 103717609B CN 201280024255 A CN201280024255 A CN 201280024255A CN 103717609 B CN103717609 B CN 103717609B
Authority
CN
China
Prior art keywords
acceptable salt
pharmaceutically acceptable
compound described
oxo
nitrae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280024255.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN103717609A (zh
Inventor
沈旺
杰克·满
张爱民
郑晓玲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Kanion Pharmaceutical Co Ltd
Original Assignee
Jiangsu Kanion Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Kanion Pharmaceutical Co Ltd filed Critical Jiangsu Kanion Pharmaceutical Co Ltd
Publication of CN103717609A publication Critical patent/CN103717609A/zh
Application granted granted Critical
Publication of CN103717609B publication Critical patent/CN103717609B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280024255.0A 2011-05-31 2012-05-31 聚(adp-核糖)聚合酶的三环抑制剂 Active CN103717609B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161491851P 2011-05-31 2011-05-31
US61/491,851 2011-05-31
PCT/US2012/040304 WO2012166983A1 (en) 2011-05-31 2012-05-31 Tricyclic inhibitors of poly(adp-ribose)polymerase

Publications (2)

Publication Number Publication Date
CN103717609A CN103717609A (zh) 2014-04-09
CN103717609B true CN103717609B (zh) 2016-05-11

Family

ID=47259874

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280024255.0A Active CN103717609B (zh) 2011-05-31 2012-05-31 聚(adp-核糖)聚合酶的三环抑制剂

Country Status (8)

Country Link
US (5) US20140221314A1 (enExample)
EP (2) EP3925962A1 (enExample)
JP (1) JP5960253B2 (enExample)
CN (1) CN103717609B (enExample)
CA (1) CA2875025C (enExample)
ES (1) ES2871052T3 (enExample)
TW (1) TWI577693B (enExample)
WO (1) WO2012166983A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3925962A1 (en) 2011-05-31 2021-12-22 Rakovina Therapeutics Inc. Tricyclic inhibitors of poly(adp-ribose) polymerase
DK2938598T3 (en) 2012-12-31 2017-02-13 Cadila Healthcare Ltd Substituted phthalazine-1 (2H) -one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
US10562886B2 (en) 2015-05-21 2020-02-18 The Regents Of The University Of California Anti-cancer compounds
WO2017223516A1 (en) 2016-06-24 2017-12-28 The Regents Of The University Of California Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
CN111936143A (zh) * 2018-04-05 2020-11-13 诺维嘉研究公司 用于治疗癌症的微管蛋白聚合抑制剂和聚(adp-核糖)聚合酶(parp)抑制剂的新型联用药品
CN119390683A (zh) 2019-08-15 2025-02-07 黑钻治疗公司 炔基喹唑啉化合物
CN112574122B (zh) * 2019-09-27 2024-05-31 上海天慈国际药业有限公司 一种奥拉帕尼关键中间体的制备方法
CN114276301B (zh) * 2020-09-27 2025-04-01 江西科睿药业有限公司 Parp抑制剂的中间体化合物及其制备方法和应用
CN112624981B (zh) * 2021-03-09 2021-05-25 南京桦冠生物技术有限公司 一种2-氟-5-[(4-氧代-3h-2,3-二氮杂萘基)甲基]苯甲酸的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101821242A (zh) * 2007-10-17 2010-09-01 库多斯药物有限公司 4-[3-(4-环丙烷羰基-哌嗪-1-羰基)-4-氟-苄基]-2h-酞嗪-1-酮

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE218556T1 (de) 1995-11-17 2002-06-15 Biotechnolog Forschung Gmbh Epothilon-derivate und deren herstellung
US6242469B1 (en) 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
JP2002536968A (ja) 1999-01-29 2002-11-05 イムクローン システムズ インコーポレイティド Ｋｄｒに特異的な抗体およびその使用
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
AU4972900A (en) 1999-04-08 2000-11-14 Arch Development Corporation Use of anti-vegf antibody to enhance radiation in cancer therapy
AU9578901A (en) 2000-10-30 2002-05-15 Kudos Pharm Ltd Phthalazinone derivatives
US7151102B2 (en) * 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7402580B2 (en) 2002-02-19 2008-07-22 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
US7196085B2 (en) 2002-04-30 2007-03-27 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
AU2004220321B2 (en) * 2003-03-12 2010-02-25 Kudos Pharmaceuticals Ltd Phthalazinone derivatives
EP1791827A1 (en) 2004-08-26 2007-06-06 Kudos Pharmaceuticals Limited 4-heteroarylmethyl substituted phthalazinone derivatives
GB0419072D0 (en) * 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
JP2009544611A (ja) * 2006-07-20 2009-12-17 メルク エンド カムパニー インコーポレーテッド ヒストン脱アセチル化酵素阻害剤としてのリン誘導体
US8466150B2 (en) 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
PT2698062E (pt) 2006-12-28 2015-10-19 Abbvie Inc Inibidores da poli (adp-ribose) polimerase
US20080280910A1 (en) 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
TW200900396A (en) 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
US20090023727A1 (en) 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
AU2008299721A1 (en) 2007-09-14 2009-03-19 Astrazeneca Ab Phthalazinone derivatives
WO2009063244A1 (en) 2007-11-15 2009-05-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Pyridazinone derivatives as parp inhibitors
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
EP2300013B2 (en) * 2008-05-21 2024-11-13 Takeda Pharmaceutical Company Limited Phosphorous derivatives as kinase inhibitors
NZ597140A (en) * 2009-06-05 2014-01-31 Cephalon Inc Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
JP5721709B2 (ja) 2009-07-02 2015-05-20 ニューゲン セラピューティクス， インコーポレイテッド リンを含むキナゾリン化合物および使用方法
EP3925962A1 (en) 2011-05-31 2021-12-22 Rakovina Therapeutics Inc. Tricyclic inhibitors of poly(adp-ribose) polymerase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101821242A (zh) * 2007-10-17 2010-09-01 库多斯药物有限公司 4-[3-(4-环丙烷羰基-哌嗪-1-羰基)-4-氟-苄基]-2h-酞嗪-1-酮

Also Published As

Publication number Publication date
WO2012166983A1 (en) 2012-12-06
US12612425B2 (en) 2026-04-28
EP3925962A1 (en) 2021-12-22
JP2014516989A (ja) 2014-07-17
EP2714703A1 (en) 2014-04-09
US20170057984A1 (en) 2017-03-02
US11248013B2 (en) 2022-02-15
TWI577693B (zh) 2017-04-11
JP5960253B2 (ja) 2016-08-02
US20180094010A1 (en) 2018-04-05
CA2875025A1 (en) 2012-12-06
US20200299315A1 (en) 2020-09-24
CA2875025C (en) 2021-08-03
ES2871052T3 (es) 2021-10-28
EP2714703A4 (en) 2014-12-31
CN103717609A (zh) 2014-04-09
EP2714703B1 (en) 2021-03-10
US20230027257A1 (en) 2023-01-26
TW201311713A (zh) 2013-03-16
US20140221314A1 (en) 2014-08-07

Similar Documents

Publication Publication Date Title
US12612425B2 (en) Tricyclic inhibitors of poly(ADP-ribose)polymerase
JP2022189853A (ja) ｍｅｎｉｎ－ＭＬＬ相互作用の阻害剤
ES2550677T3 (es) Triazolopiridinas sustituidas y su uso como inhibidores de TTK
CN111201223A (zh) SHP2的八氢环戊二烯并[c]吡咯别构抑制剂
KR102642063B1 (ko) 칼슘 채널 억제제
KR20180026537A (ko) Irak-4 저해제로서 치환된 아자 화합물
WO2023174329A1 (en) Heteroaromatic compounds as pkmyt1 inhibitors and use thereof
US9073918B2 (en) Pyrazolo[4,3-b]pyridine-7-amine inhibitors of ALK5
US12508263B2 (en) Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof
CN118055933A (zh) 选择性parp1抑制剂及其应用
US20180215738A1 (en) Inhibitors of ack1/tnk2 tyrosine kinase
CN120225520A (zh) 化合物和其用途
WO2015021149A1 (en) Inhibitors of ack1/tnk2 tyrosine kinase
KR20260019517A (ko) 3,4-디히드로프탈라진-1(2h)-온 유도체, 및 이의 제조 방법 및 이의 용도
CN105339356B (zh) 酞嗪衍生物
WO2017097113A1 (zh) 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物
CN115960109B (zh) 稠环类shp2磷酸酶抑制剂的制备及其应用
US20230212174A1 (en) Pyrrolo[2,1-f][1,2,4]triazine derivative and use thereof
HK40079587B (zh) 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用
HK40029610B (zh) 一种哒嗪类衍生物抑制剂、其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant